Drugs / BPI-371153
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05341557 | Aug 2022 → Dec 2026 expected | hepatocellular carcinoma, lymphoma, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-371153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05341557 ↗ |
| Action | Inhibit | “BPI-371153, a PD-L1 Inhibitor” NCT05341557 ↗ |
| Route | Oral | “Oral capsules taken in escalating levels” NCT05341557 ↗ |